Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
New multiple sclerosis phenotypic classification.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Genzyme’s Lemtrada Approved by the FDA
Tcelna® (imilecleucel-T)
More to come: humoral immune responses in MS.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Biogen Idec's long-acting beta interferon moves ahead in MS
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Arzerra
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Pages